<?xml version='1.0' encoding='utf-8'?>
<document id="30002078"><sentence text="Biotransformation of Ilaprazole in Human Liver Microsomes and Human: Role of CYP3A4 in Ilaprazole Clearance and Drug-Drug Interaction."><entity charOffset="21-31" id="DDI-PubMed.30002078.s1.e0" text="Ilaprazole" /><entity charOffset="87-97" id="DDI-PubMed.30002078.s1.e1" text="Ilaprazole" /><pair ddi="false" e1="DDI-PubMed.30002078.s1.e0" e2="DDI-PubMed.30002078.s1.e0" /><pair ddi="false" e1="DDI-PubMed.30002078.s1.e0" e2="DDI-PubMed.30002078.s1.e1" /></sentence><sentence text="Ilaprazole is a new proton pump inhibitor and is currently marketed in China and South Korea for the treatment of gastric and duodenal ulcer"><entity charOffset="0-10" id="DDI-PubMed.30002078.s2.e0" text="Ilaprazole" /></sentence><sentence text=" Ilaprazole has a favorable long half-life and minimal pharmacokinetic variability associated with CYP2C19 polymorphism"><entity charOffset="1-11" id="DDI-PubMed.30002078.s3.e0" text="Ilaprazole" /></sentence><sentence text=" Sulfoxide oxidation of ilaprazole is catalyzed mainly by CYP3A4"><entity charOffset="1-10" id="DDI-PubMed.30002078.s4.e0" text="Sulfoxide" /><entity charOffset="24-34" id="DDI-PubMed.30002078.s4.e1" text="ilaprazole" /><pair ddi="false" e1="DDI-PubMed.30002078.s4.e0" e2="DDI-PubMed.30002078.s4.e0" /><pair ddi="false" e1="DDI-PubMed.30002078.s4.e0" e2="DDI-PubMed.30002078.s4.e1" /></sentence><sentence text=" Thus, it has been widely accepted that CYP3A4 plays a major role in the clearance of ilaprazole in humans"><entity charOffset="86-96" id="DDI-PubMed.30002078.s5.e0" text="ilaprazole" /></sentence><sentence text=" However, absorption, distribution, metabolism, and excretion data of radiolabeled ilaprazole in humans are not available"><entity charOffset="83-93" id="DDI-PubMed.30002078.s6.e0" text="ilaprazole" /></sentence><sentence text=" The primary goal of this study was to determine if sulfoxide oxidation is a major metabolic pathway of ilaprazole in humans"><entity charOffset="52-61" id="DDI-PubMed.30002078.s7.e0" text="sulfoxide" /><entity charOffset="104-114" id="DDI-PubMed.30002078.s7.e1" text="ilaprazole" /><pair ddi="false" e1="DDI-PubMed.30002078.s7.e0" e2="DDI-PubMed.30002078.s7.e0" /><pair ddi="false" e1="DDI-PubMed.30002078.s7.e0" e2="DDI-PubMed.30002078.s7.e1" /></sentence><sentence text=" Metabolite profiles of ilaprazole, ilaprazole sulfide, and ilaprazole sulfone in human liver microsomes (HLMs) were characterized and quantitively analyzed by liquid chromatography (LC)/UV/high-resolution mass spectrometry (HRMS)"><entity charOffset="24-34" id="DDI-PubMed.30002078.s8.e0" text="ilaprazole" /><entity charOffset="36-54" id="DDI-PubMed.30002078.s8.e1" text="ilaprazole sulfide" /><entity charOffset="60-78" id="DDI-PubMed.30002078.s8.e2" text="ilaprazole sulfone" /><pair ddi="false" e1="DDI-PubMed.30002078.s8.e0" e2="DDI-PubMed.30002078.s8.e0" /><pair ddi="false" e1="DDI-PubMed.30002078.s8.e0" e2="DDI-PubMed.30002078.s8.e1" /><pair ddi="false" e1="DDI-PubMed.30002078.s8.e0" e2="DDI-PubMed.30002078.s8.e2" /><pair ddi="false" e1="DDI-PubMed.30002078.s8.e1" e2="DDI-PubMed.30002078.s8.e1" /><pair ddi="false" e1="DDI-PubMed.30002078.s8.e1" e2="DDI-PubMed.30002078.s8.e2" /></sentence><sentence text=" Moreover, metabolites of ilaprazole in human urine and feces were detected and identified by LC-HRMS"><entity charOffset="26-36" id="DDI-PubMed.30002078.s9.e0" text="ilaprazole" /></sentence><sentence text=" The results revealed that sulfoxide reduction to ilaprazole sulfide rather than sulfoxide oxidation was the major biotransformation pathway in HLMs"><entity charOffset="27-36" id="DDI-PubMed.30002078.s10.e0" text="sulfoxide" /><entity charOffset="50-68" id="DDI-PubMed.30002078.s10.e1" text="ilaprazole sulfide" /><entity charOffset="81-90" id="DDI-PubMed.30002078.s10.e2" text="sulfoxide" /><pair ddi="false" e1="DDI-PubMed.30002078.s10.e0" e2="DDI-PubMed.30002078.s10.e0" /><pair ddi="false" e1="DDI-PubMed.30002078.s10.e0" e2="DDI-PubMed.30002078.s10.e1" /><pair ddi="false" e1="DDI-PubMed.30002078.s10.e0" e2="DDI-PubMed.30002078.s10.e2" /><pair ddi="false" e1="DDI-PubMed.30002078.s10.e1" e2="DDI-PubMed.30002078.s10.e1" /><pair ddi="false" e1="DDI-PubMed.30002078.s10.e1" e2="DDI-PubMed.30002078.s10.e2" /></sentence><sentence text=" Sulfoxide reduction also occurred in HLMs without NADPH or in deactivated HLMs"><entity charOffset="1-10" id="DDI-PubMed.30002078.s11.e0" text="Sulfoxide" /><entity charOffset="51-56" id="DDI-PubMed.30002078.s11.e1" text="NADPH" /><pair ddi="false" e1="DDI-PubMed.30002078.s11.e0" e2="DDI-PubMed.30002078.s11.e0" /><pair ddi="false" e1="DDI-PubMed.30002078.s11.e0" e2="DDI-PubMed.30002078.s11.e1" /></sentence><sentence text=" Ilaprazole sulfide and its multiple oxidative metabolites were major drug-related components in human urine and feces, where there were no ilaprazole sulfone and its metabolites"><entity charOffset="1-19" id="DDI-PubMed.30002078.s12.e0" text="Ilaprazole sulfide" /><entity charOffset="140-158" id="DDI-PubMed.30002078.s12.e1" text="ilaprazole sulfone" /><pair ddi="false" e1="DDI-PubMed.30002078.s12.e0" e2="DDI-PubMed.30002078.s12.e0" /><pair ddi="false" e1="DDI-PubMed.30002078.s12.e0" e2="DDI-PubMed.30002078.s12.e1" /></sentence><sentence text=" A small amount of the parent drug was found in feces" /><sentence text=" Thus, we propose that nonenzymatic sulfoxide reduction rather than CYP3A4-medidated sulfoxide oxidation is the major metabolic clearance pathway of ilaprazole in humans"><entity charOffset="23-45" id="DDI-PubMed.30002078.s14.e0" text="nonenzymatic sulfoxide" /><entity charOffset="85-94" id="DDI-PubMed.30002078.s14.e1" text="sulfoxide" /><entity charOffset="149-159" id="DDI-PubMed.30002078.s14.e2" text="ilaprazole" /><pair ddi="false" e1="DDI-PubMed.30002078.s14.e0" e2="DDI-PubMed.30002078.s14.e0" /><pair ddi="false" e1="DDI-PubMed.30002078.s14.e0" e2="DDI-PubMed.30002078.s14.e1" /><pair ddi="false" e1="DDI-PubMed.30002078.s14.e0" e2="DDI-PubMed.30002078.s14.e2" /><pair ddi="false" e1="DDI-PubMed.30002078.s14.e1" e2="DDI-PubMed.30002078.s14.e1" /><pair ddi="false" e1="DDI-PubMed.30002078.s14.e1" e2="DDI-PubMed.30002078.s14.e2" /></sentence><sentence text=" Consequently, it is predicted that ilaprazole has no significant drug-drug interaction via CYP3A4 inhibition or induction by a coadministered drug"><entity charOffset="36-46" id="DDI-PubMed.30002078.s15.e0" text="ilaprazole" /></sentence><sentence text="" /></document>